Dean Schorno
Directeur Financier/CFO chez RIGEL PHARMACEUTICALS, INC.
Fortune : 331 176 $ au 30/06/2024
Profil
Dean L.
Schorno is currently the Chief Financial Officer & Executive Vice President at Rigel Pharmaceuticals, Inc. Prior to his current position, he served as the Chief Financial Officer & Head-Investor Relations at Genomic Health, Inc. from 2011 to 2014.
From 2015 to 2018, he held the role of Chief Financial Officer & Head-Operations at 23andMe, Inc. Additionally, he was the Chief Financial Officer at Adaptive Biotechnologies Corp.
from 2014 to 2015.
Mr. Schorno completed his graduate degree at Golden Gate University and his undergraduate degree at the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/02/2024 | 40 289 ( 0,23% ) | 331 176 $ | 30/06/2024 |
Postes actifs de Dean Schorno
| Sociétés | Poste | Début |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Directeur Financier/CFO | 29/05/2018 |
Anciens postes connus de Dean Schorno
| Sociétés | Poste | Fin |
|---|---|---|
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | Directeur Financier/CFO | 01/05/2018 |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Directeur Financier/CFO | 10/08/2015 |
| GENOMIC HEALTH, INC. | Directeur Financier/CFO | 01/07/2014 |
Formation de Dean Schorno
| University of California, Berkeley | Undergraduate Degree |
| Golden Gate University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Genomic Health, Inc.
 Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | Health Technology |
